Findings shared here were originally presented in a poster session at ACT 2025

Toxicologic Profiles of Lipid Nanoparticle (LNP) Used as Delivery Systems for Nucleic Acid Therapeutics in Cynomolgus Monkeys: Insights From Cross-Study Analysis of Various LNP Formulations

A Comparative Study of Ocular Anatomy in Three Different Laboratory Swine Strains

Standardizing Immunomodulatory Dosing of Sirolimus in Nonhuman Primates for Gene Therapy: A Data-Driven Review

Lacrimal Gland Measurements in Most Common Preclinical Laboratory Animals

Comparison of Baseline Levels of Biomarkers Commonly Used to Assess Drug Candidate Safety, Efficacy, and Mechanism of Action in Cynomolgus Monkeys of Cambodian, Chinese, or Cambodian-Chinese Mixed Origin Bred in a U.S.-Based Research Facility

Drug development is not for the faint of heart; a twist on the Hunger Games saying, “May the odds be (n)ever in your favor,” might adequately characterizes the challenge. As scientists, however, we manage these inherent risks by establishing best practices and learning from our collective successes and failures, as well as. In this field, experience truly matters.

Subscribe to